Dr. Jahanzeb on the APHINITY and ExteNET Trials in Breast Cancer

Mohammad Jahanzeb, MD, FACP, on the impact of the APHINITY study presented at ASCOПодробнее

Dr. Jahanzeb Discusses Advancements in Adjuvant HER2+ Breast CancerПодробнее

Dr. Jahanzeb on Overcoming HER2 Resistance in Breast CancerПодробнее

Adjuvant Therapy Data for HER2-Positive Breast CancerПодробнее

Dr. Yardley on the APHINITY Trial for HER2-Positive Breast CancerПодробнее

Dr. Jahanzeb on the Future of Adjuvant Therapy in HER2+ Breast CancerПодробнее

APHINITY Trial in HER2+ Breast CancerПодробнее

Dr. Mohammad Jahanzeb on Neratinib and Trastuzumab in HER2-Positive Breast CancerПодробнее

Dr. Chan on ExteNET Trial for HER2+ Breast CancerПодробнее

Understanding the ExteNET TrialПодробнее

The ExteNET TrialПодробнее

Breast Cancer: Extended Adjuvant Therapy and Cost FactorsПодробнее

Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozoleПодробнее

Dr. D’Abreo on Extended Therapy Trials in Breast CancerПодробнее

APHINITY Trial: Adjuvant HER2-Targeted Therapy in HER2+ BCПодробнее

Chemotherapy With Adjuvant Therapy in Breast CancerПодробнее

The ExteNET Study & Management of HER2+ Breast CancerПодробнее

Dr. Crew on the APHINITY Trial Results in HER2+ Breast CancerПодробнее

ExteNET and NEfERTT Clinical Studies in Metastatic Breast CancerПодробнее